About the Project

TOPCAPI is a collaboration between academic and industrial partners from around Europe that will harness the biosynthetic power of actinomycete bacteria to create microbial cell factories for the production of high-value pharmaceuticals, in particular antibiotics.

50% of all drugs are derived from, or inspired by, natural sources, many of them actinomycetes. Thus, actinomycetes are evolutionarily optimised to be producers of natural products, making them potentially the best production host for high-value compounds.

However, up until now, there is no single, robust actinomycete cell factory available for high-level production of different compounds in an industrial context.



  • Use systems biology approaches to achieve industry-level improved performance of established actinomycete platforms.
  • Use metabolic modelling approaches to engineer the biosynthesis pathways of target compounds.
  • Optimise the expression of the engineered target pathways in pre-engineered strains to achieve industrially viable production levels of target compounds.

 Read the press release here


TOPCAPI: Thoroughly Optimised Production Chassis for Advanced Pharmaceutical Ingredients,  began on 1st January 2017 .

The programme of research will run for four years.

The project is coordinated by the University of Manchester (UK) with partners drawn from four European countries, Spain, Italy, UK and Slovenia.


TOPCAPI Partners

This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant Agreement No. 720793